The opposition filed by Blink against the SSB European Patent in the European Patent Office has been rejected by the Opposition Division of the European Patent Office and the SSB European Patent has been maintained, whereupon Blink has filed an appeal against such decision with the European Patent Office and the appeal has been referred to the Board of Appeal of the European Patent Office under File Number [[Identifier]]. On June 4, 2018, Forty Seven acquired the opposition appeal from Blink as a business asset, along the all of other assets of Blink’s anti-CD47 program (the “BliNK Asset Acquisition”). Subsequently, the appeal opposition has been transferred from Blink to Forty Seven in the European Patent Office.

Blink (as identified and defined hereinafter) has filed an opposition to the SSB European Patent (as hereinafter defined) in the European Patent Office. Forty Seven has filed third party observations in the opposition to the SSB European Patent and has collaborated with Blink in the opposition.